UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.158

Sortiert nach

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823

2017

Volltextzugriff (PDF)

A critical review of Real Options thinking for valuing investment flexibility in Smart Grids and low carbon energy systems

Renewable & sustainable energy reviews, 2016-04, Vol.56, p.261-271

2016

Volltextzugriff (PDF)

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

The New England journal of medicine, 2019-08, Vol.381 (7), p.626-636

2019

Volltextzugriff (PDF)

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

Annals of oncology, 2017-03, Vol.28 (3), p.634-641

2017

Volltextzugriff (PDF)

Simultaneous Optogenetics and Cellular Resolution Calcium Imaging During Active Behavior Using a Miniaturized Microscope

Frontiers in neuroscience, 2018-07, Vol.12, p.496-496

2018

Volltextzugriff (PDF)

Dendritic spikes amplify the synaptic signal to enhance detection of motion in a simulation of the direction-selective ganglion cell

PLoS computational biology, 2010-08, Vol.6 (8), p.e1000899

2010

Volltextzugriff (PDF)

Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice

Neurobiology of disease, 2018-10, Vol.118, p.161-176

2018

Volltextzugriff (PDF)

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

Annals of oncology, 2022-02, Vol.33 (2), p.204-215

2022

Volltextzugriff (PDF)

Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]

Annals of oncology, 2022-08, Vol.33 (8), p.853-853

2022

Volltextzugriff (PDF)

Extracellular ATP hydrolysis in Caco-2 human intestinal cell line

Biochimica et biophysica acta. Biomembranes, 2021-10, Vol.1863 (10), p.183679-183679, Article 183679

2021

Volltextzugriff (PDF)

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16_suppl), p.9569-9569

2022

Volltextzugriff (PDF)

In vivo Calcium Imaging Reveals That Cortisol Treatment Reduces the Number of Place Cells in Thy1-GCaMP6f Transgenic Mice

Frontiers in neuroscience, 2019-03, Vol.13, p.176-176

2019

Volltextzugriff (PDF)

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

Annals of oncology, 2018-10, Vol.29, p.viii442-viii442

2018

Volltextzugriff (PDF)

CEACAM1 in malignant melanoma: a diagnostic and therapeutic target

Current topics in medicinal chemistry, 2012, Vol.12 (1), p.3

2012

Volltextzugriff (PDF)

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Journal of clinical oncology, 2000-02, Vol.18 (4), p.724-733

2000

Volltextzugriff (PDF)

Immunotherapy of distant metastatic disease

Annals of oncology, 2009-08, Vol.20 (suppl-6), p.vi41-vi50

2009

Volltextzugriff (PDF)

IN VITRO ANALYSIS PREDICTS CLINICAL RESPONSE OF B CELL LYMPHATIC MALIGNANCIES TO CD19 CAR‐T CELLS: PHENOTYPIC, TRANSCRIPTIONAL AND FUNCTIONAL STUDY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Performance of the APTIMA Combo 2 Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Female Urine and Endocervical Swab Specimens

Journal of Clinical Microbiology, 2003-01, Vol.41 (1), p.304-309

2003

Volltextzugriff (PDF)

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial

Annals of oncology, 2018-10, Vol.29, p.viii445-viii445

2018

Volltextzugriff (PDF)

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

Annals of oncology, 2018-10, Vol.29, p.viii446-viii446

2018

Volltextzugriff (PDF)

Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies

European journal of cancer (1990), 2017-02, Vol.72, p.S123-S123

2017

Volltextzugriff (PDF)

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

European journal of cancer (1990), 2017-02, Vol.72, p.S128-S129

2017

Volltextzugriff (PDF)

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Journal of Immunology Research, 2015-01, Vol.2015, p.902137-8

2015

Volltextzugriff (PDF)

Multicenter Evaluation of the BDProbeTec ET System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Urine Specimens, Female Endocervical Swabs, and Male Urethral Swabs

Journal of Clinical Microbiology, 2001-03, Vol.39 (3), p.1008-1016

2001

Volltextzugriff (PDF)

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

European journal of cancer (1990), 2015-09, Vol.51, p.S664-S665

2015

Volltextzugriff (PDF)

1 – 25 von 2.158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.699)
Mit Volltextzugriff
(1.618)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.201)
Humans
(1.046)
Life Sciences & Biomedicine
(1.042)
Female
(570)
Biological And Medical Sciences
(510)
Male
(495)
Medical Sciences
(418)
Adult
(367)
Animals
(289)
Middle Aged
(227)
Infectious Diseases
(208)
Immunology
(183)
Adolescent
(169)
Child
(144)
Chlamydia Trachomatis
(136)
General & Internal Medicine
(125)
Microbiology
(115)
Aged
(111)
Fundamental And Applied Biological Sciences. Psychology
(111)
Physical Sciences
(110)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

A critical review of Real Options thinking for valuing investment flexibility in Smart Grids and low carbon energy systems

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

Simultaneous Optogenetics and Cellular Resolution Calcium Imaging During Active Behavior Using a Miniaturized Microscope

Dendritic spikes amplify the synaptic signal to enhance detection of motion in a simulation of the direction-selective ganglion cell

Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]

Extracellular ATP hydrolysis in Caco-2 human intestinal cell line

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study

In vivo Calcium Imaging Reveals That Cortisol Treatment Reduces the Number of Place Cells in Thy1-GCaMP6f Transgenic Mice

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

CEACAM1 in malignant melanoma: a diagnostic and therapeutic target

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Immunotherapy of distant metastatic disease

IN VITRO ANALYSIS PREDICTS CLINICAL RESPONSE OF B CELL LYMPHATIC MALIGNANCIES TO CD19 CAR‐T CELLS: PHENOTYPIC, TRANSCRIPTIONAL AND FUNCTIONAL STUDY

Performance of the APTIMA Combo 2 Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Female Urine and Endocervical Swab Specimens

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Multicenter Evaluation of the BDProbeTec ET System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Urine Specimens, Female Endocervical Swabs, and Male Urethral Swabs

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

Suchergebnisse filtern